NASDAQ
10.11.26 | 22:00
1,110 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 28.09. | ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer | 3 | GlobeNewswire (USA) | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 14.09. | ALX Oncology auf H.C. Wainwright Konferenz: Zwei Wirkstoffkandidaten vor entscheidenden Tests | 5 | Investing.com Deutsch | ||
| 10.09. | ALX Oncology auf Gesundheitskonferenz von Cantor: Biomarker-Strategie rückt in den Fokus | 1 | Investing.com Deutsch | ||
| 06.08. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | ALX Oncology GAAP EPS of -$0.13 | 1 | Seeking Alpha | ||
| 06.08. | ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 858 | GlobeNewswire (Europe) | - On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive... ► Artikel lesen | |
| 06.08. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 30.06. | ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules | 3 | GlobeNewswire (USA) | ||
| 30.06. | ALX Oncology names Scott Garland chairman, adds general counsel | 2 | Investing.com | ||
| 30.06. | ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel | 2 | GlobeNewswire (USA) | ||
| 26.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 3 | SEC Filings | ||
| 11.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update | 794 | GlobeNewswire (Europe) | - Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable... ► Artikel lesen | |
| 07.05. | ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression | 329 | GlobeNewswire (Europe) | - Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the... ► Artikel lesen | |
| 13.04. | ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer | 332 | GlobeNewswire (Europe) | - Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13... ► Artikel lesen | |
| 10.03. | Rüstungs-Rallye nach Iran-Angriff: Rheinmetall, Palantir, DroneShield und Harvest Technology im Fokus der Anleger | Small- & Micro Cap Investment | |||
| 27.02. | ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 847 | GlobeNewswire (Europe) | - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company... ► Artikel lesen | |
| 08.01. | ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 | 223 | GlobeNewswire (Europe) | - First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim... ► Artikel lesen | |
| 07.12.25 | ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting | 349 | GlobeNewswire (Europe) | - Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,098 | -0,64 % | Evotec Aktie: 95 Prozent verloren - kommt jetzt die Wende? | Um die Evotec Aktie ranken sich immer wieder Spekulationen und Hoffnungen auf eine Trendwende, im Chart ist davon bislang wenig zu sehen. Lange Zeit war die 200-Tage-Linie die Hürde, an der jede Erholung... ► Artikel lesen | |
| MODERNA | 228,70 | +1,73 % | Moderna: WHO-Expertengremium empfiehlt Ebola-Impfstoff für Phase-2/3-Studie | Moderna hat bei der Entwicklung eines Impfstoffs gegen das Bundibugyo-Ebolavirus einen weiteren Schritt erreicht. Eine technische Beratergruppe der Weltgesundheitsorganisation WHO empfiehlt, den experimentellen... ► Artikel lesen | |
| NOVAVAX | 9,050 | -0,88 % | Novavax, Inc.: Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights | Reports total revenue of $68 million for the third quarter of 2026Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 41,330 | +1,39 % | 99 Millionen Dollar mit neuer Gentherapie: Vertex und CRISPR Therapeutics legen zu - Mesoblast wächst um 44 Prozent | ||
| INOVIO PHARMACEUTICALS | 1,195 | -7,72 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights | VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,200 | +1,80 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DEFENCE THERAPEUTICS | 0,191 | -9,29 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,340 | +4,00 % | Editas auf der Guggenheim Healthcare Innovation Conference: Strategischer Fokus auf In-vivo-CRISPR | ||
| HALOZYME THERAPEUTICS | 92,22 | -0,04 % | Halozyme Therapeutics, Inc.: U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE Technology for the Treatment of Advanced Head and Neck Cancer | Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 51,10 | -0,20 % | BioMarin-Aktie: Ein Kauf vor 2027 könnte sich lohnen | Die BioMarin-Aktie bietet nach einem deutlichen Kursrückgang und einer inzwischen günstigen Bewertung wieder Chancen für kurz- und langfristig orientierte Anleger. Drei anstehende FDA-Entscheidungen... ► Artikel lesen | |
| EXELIXIS | 63,63 | +0,65 % | Exelixis, Inc.: Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November | - Presentations to be webcast on www.exelixis.comExelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:Guggenheim... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,580 | -0,82 % | Sarepta Therapeutics auf Guggenheim-Konferenz: Starker Cashflow finanziert breite Entwicklungspipeline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,040 | +1,44 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 10-Q, Quarterly Report | ||
| NEUROCRINE BIOSCIENCES | 149,75 | -1,16 % | Rund 21 Prozent weniger Tic-Schwere im Pilotversuch: Was Neurotheras Tourette-Studie in Hannover klären soll | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc. - 8-K, Current Report |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,110 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.